Study May Aid AYAs in Weighing Risks, Benefits of Clinical Trial Participation
Trends in favor of better clinical outcomes were observed for those on-trial in this retrospective matched cohort study of patients with cancer who were treated on a phase III clinical trial compared with those who received standard therapy and/or were off trial. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Patients See Benefit with Telemedicine Visits Compared with In-Person Visits
It was suggested that telemedicine for patients in an interventional radiology group increases access to care and allows for more efficient use of physician time and resources. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Study Supports Increased Referrals of Genetic Testing in African American Women
A recent study demonstrated the validity of current breast cancer testing panels for use in African American women and provides a basis for increased referral of this patient population for cancer genetic testing. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Source Type: news

Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma
The combination use of belantamab mafodotin plus bortezomib   and dexamethasone induced high clinical benefit rates and a tolerable safety profile in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news

Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma
Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos, MD Source Type: news

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial
The trial compared zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenstr öm macroglobulinemia. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA Source Type: news

Clinical Improvement Found After Administration of Acalabrutinib for Patients with COVID-19
A recent study, sparking further trials for investigation, saw improved clinical outcomes and reduced markers of inflammation for patients with severe COVID-19 after treatment with acalabrutinib, a selective BTK inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Tony Berberabe, MPH Source Type: news

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings
The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news

Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma
The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2020 Category: Cancer & Oncology Authors: Jason M. Broderick Source Type: news

ASCO Expert Discusses the Use of Autologous Transplantation in Relapsed DLBCL
Nirav Niranjan Shah, MD, spoke about the use of autologous stem cell transplant in patients with relapsed, chemosensitive DLBCL during the era of CAR T-cell therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2020 Category: Cancer & Oncology Authors: Nirav Niranjan Shah, MD Source Type: news

Quiz: When to Use Endoscopy for Acute Upper Gastrointestinal Bleeding
In our gastrointestinal cancer quiz, you ’ll get a chance to test your knowledge on the use of endoscopy for acute upper gastrointestinal bleeding. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Parameswaran Hari, MD, MRCP Source Type: news

CC-92480 Plus Dexamethasone Shows Favorable Activity in Relapsed/Refractory Myeloma
CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Dylann Cohn-Emery Source Type: news